Radiotherapy for hypopharynx cancers

Autor: Pointreau, Y., Biau, J., Delaby, N., Thariat, J., Lapeyre, M.
Přispěvatelé: Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)
Rok vydání: 2021
Předmět:
MESH: Hypopharyngeal Neoplasms
MESH: Pharyngectomy
Intensity-modulated radiotherapy
Recommandations
French Society of Radiation Oncology
Hypopharynx cancer
[SDV.CAN]Life Sciences [q-bio]/Cancer
Laryngectomy
Radiothérapie conformationnelle avec modulation d’intensité
Doses
Pharyngectomy
Délinéation
MESH: Lymphatic Irradiation
Humans
Radiology
Nuclear Medicine and imaging
MESH: Chemoradiotherapy
MESH: Humans
Hypopharyngeal Neoplasms
Lymphatic Irradiation
Tumeurs hypopharyngée
Delineation
MESH: Radiotherapy
Intensity-Modulated
Chemoradiotherapy
Induction Chemotherapy
Recommendation
MESH: Laryngectomy
MESH: Induction Chemotherapy
MESH: Radiation Oncology
Indication
MESH: France
Oncology
Dose
Radiation Oncology
Dose Fractionation
Radiation
France
Radiotherapy
Intensity-Modulated
Indications
MESH: Dose Fractionation
Radiation
Société française de radiothérapie oncologique
Zdroj: Cancer/Radiothérapie
Cancer/Radiothérapie, 2022, 26 (1-2), pp.199-205. ⟨10.1016/j.canrad.2021.10.006⟩
ISSN: 1769-6658
1278-3218
DOI: 10.1016/j.canrad.2021.10.006⟩
Popis: International audience; We present the update of the recommendations of the French society of oncological radiotherapy on radiotherapy for hypopharynx. Intensity-modulated radiotherapy is the gold standard treatment for hypopharynx cancers. Early T1 and T2 tumors could be treated by exclusive radiotherapy or surgery followed by postoperative radiotherapy in case of high recurrence risk. For locally advanced tumours requiring total pharyngolaryngectomy (T2 or T3) or with significant lymph nodes involvement, induction chemotherapy followed by exclusive radiotherapy or concurrent chemoradiotherapy were possible. For T4 tumour, surgery must be proposed. The treatment of lymph nodes is based on initial primary tumour treatment. In non-surgical procedure, for 35 fractions, curative dose is 70Gy (2Gy per fraction) and prophylactic dose are 50 to 56Gy (2Gy per fraction in case of sequential radiotherapy or 1.6Gy in case of integrated simultaneous boost) radiotherapy; for 33 fractions, curative dose is 69.96Gy (2.12Gy per fraction) and prophylactic dose is 52.8Gy (1.6Gy per fraction in integrated simultaneous boost radiotherapy or 54Gy in 1.64Gy per fraction); for 30 fractions, curative dose is 66Gy (2.2Gy per fraction) and prophylactic dose is 54Gy (1.8Gy per fraction in integrated simultaneous boost radiotherapy). Doses over 2Gy per fraction could be done when chemotherapy is not used regarding potential larynx toxicity. Postoperatively, radiotherapy is used in locally advanced cancer with dose levels based on pathologic criteria, 60 to 66Gy for R1 resection and 54 to 60Gy for complete resection in bed tumour; 50 to 66Gy in lymph nodes areas regarding extracapsular spread. Volume delineation were based on guidelines cited in this article.
Databáze: OpenAIRE
Externí odkaz: